Thank you for your deep dive. Very interesting, I will hold an eye on this company. This reminds me on Immunitybio, only in oncology, but also with several platforms (bispecific antibodies, Car-NK and adenovirus platform). But in contrast to ABCL IBRX does have a PDUFA date for the first drug Anktiva this month. I did a deep dive in their platforms and summarised it here: https://optionicity.com/biotech/ibrx/platform.shtml . Feel free to use the data also from the many clinical trials.
Thank you for your deep dive. Very interesting, I will hold an eye on this company. This reminds me on Immunitybio, only in oncology, but also with several platforms (bispecific antibodies, Car-NK and adenovirus platform). But in contrast to ABCL IBRX does have a PDUFA date for the first drug Anktiva this month. I did a deep dive in their platforms and summarised it here: https://optionicity.com/biotech/ibrx/platform.shtml . Feel free to use the data also from the many clinical trials.
Happy to have inspired you 🙏
Looking forward to reading accurately and discuss it with you!